Susquehanna International Group’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

Susquehanna International Group’s Portfolio SGTX Stock Details SGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-11,031	Closed	-$80.1K	–	13666
2023 Q1	$133K	Buy	11,031 +3,341	+43%	+$34.7K	﹤0.01%	11026
2022 Q4	$35K	Sell	7,690 -1,155	-13%	-$6.59K	﹤0.01%	11571
2022 Q3	$58K	Buy	8,845 +3,793	+75%	+$34.6K	﹤0.01%	12109
2022 Q2	$55K	Buy	5,052 +3,663	+264%	+$49.3K	﹤0.01%	11931
2022 Q1	$27K	Sell	1,389 -1,928	-58%	-$43K	﹤0.01%	12541
2021 Q4	$119K	Buy	3,317 +1,446	+77%	+$82.3K	﹤0.01%	12011
2021 Q3	$137K	Buy	+1,871	New	+$144K	﹤0.01%	11860

Other funds holding SGTX

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Susquehanna International Group's SGTX Position: Q2 2023 in Review

Susquehanna International Group sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q2 2023, closing a stake of 11,031 shares — an estimated $80.1K sold.

Susquehanna International Group first reported a position in SGTX in Q3 2021 and held it in 7 quarters. The position peaked at $137K in Q3 2021. 16 funds tracked by Wall St. Rank hold SGTX as of Q2 2023.

Susquehanna International Group reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Susquehanna International Group sold 11,031 Sigilon Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $80.1K.
Susquehanna International Group first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q3 2021 and held it in 7 quarters.
Susquehanna International Group's Sigilon Therapeutics, Inc. Common Stock position peaked at $137K in Q3 2021.
16 funds tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Susquehanna International Group's 13F filing for Q2 2023, filed 11 Aug 2023.